RPRX Royalty Pharma Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
01:25
Jan 23
Jim Cramer Host, Mad Money CNBC
Loves Royalty Pharma's biotech funding model.
Cramer loves Royalty Pharma's business model of helping fund biotech and earning returns, says the stock just keeps going higher and calls it a terrific company.
RPRX
HIGH
01:01
Jan 23
Jim Cramer Host, Mad Money CNBC
Royalty Pharma's biopharma funding model works
Royalty Pharma keeps going higher; Cramer loves its step-function business model of funding biopharma and earning returns, and he has liked the company since its IPO.
RPRX 1ST
MED

About RPRX Investor Commentary

Across the available history and selected sources, Buzzberg tracks RPRX (Royalty Pharma) across 1 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Jim Cramer.